New & Notable
CMMI to launch model to lower Medicaid drug spending
Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in select other countries with participating pharmaceutical manufacturers.
— Healthcare Dive
FDA expands the National Priority Voucher program to oral GLP-1s
The FDA's second wave of National Priority Voucher recipients includes Novo Nordisk and Eli Lilly's oral GLP-1s, expanding the list to 15 products.
Novo, Lilly cut deal with Trump to lower prices of obesity drugs
The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.
— Biopharma Dive
Lilly advances amylin obesity drug eloralintide to phase 3 trials
Eli Lilly is set to begin late-stage clinical trials of its investigational amylin obesity drug next month, after encouraging phase 2 study results.
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Report: Compounded GLP-1 drugs pose safety, quality risks
Compounded GLP-1 drugs pose safety and quality risks, a recent report says, adding to the growing calls for tougher regulatory enforcement.
-
CVS Rx Report: 5 latest trends influencing community pharmacy
CVS Health's 2025 Rx Report highlights key community pharmacy trends, showing how patient needs, workforce pressures and sustainable care models are shaping care.
-
AstraZeneca joins Pfizer in most-favored nation pricing program
AstraZeneca joins Pfizer in the White House's most favored nation drug pricing program, expanding TrumpRx's reach but raising questions about real-world savings.
-
GLP-1 drugs can interfere with FDG-PET-CT scans, study says
Taking GLP-1 receptor agonists can cause atypical tracer uptake patterns in the body that could be mistaken for inflammation or cancer in FDG-PET-CT scans.
-
Amazon Pharmacy debuts drug-dispensing kiosks at One Medical
Amazon Pharmacy will install drug-dispensing kiosks at select One Medical offices in Los Angeles beginning in December, with plans to expand outside California in 2026.
-
Survey: Pharmacists overwhelmed by volume over value
Most pharmacists feel overwhelmed by competing job demands, which limit patient-centered care for those managing diabetes, a new CCS report finds.
Features
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.
-
Expanding clinical trial access through technology, support
Systemic barriers continue to restrict clinical trial access, but when deployed correctly, technology can provide patient–provider support and close interoperability gaps.
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.